Skip to content

Exploring the efficacy of repetitive transcranial magnetic stimulation for Tourette syndrome

Exploring the efficacy of repetitive transcranial magnetic stimulation for Tourette syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095106
Enrollment
Unknown
Registered
2025-01-02
Start date
2025-01-04
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tourette syndrome

Interventions

FC-group:Functional connectivity-guided rTMS targeting was used with 1 Hz stimulation administered twice daily (morning and afternoon) for two consecutive weeks. Each session involved 1,800 pulses at
T Group:Traditional Localization Group Stimulation Coordinates: The stimulation site is the left supplementary motor area (SMA), determined according to relevant literature as being located at 15% of

Sponsors

Hangzhou Normal University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-40 years; 2. Diagnosis of Tourette syndrome (based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5]); 3. Wechsler Intelligence Scale score above 80; 4. Yale Global Tic Severity Scale (YGTSS) total motor + vocal tic score >= 20; 5. Minimal comorbidities, with no significant psychiatric symptoms; 6. At least six months of regular pharmacotherapy with unsatisfactory outcomes; 7. Able to accept TMS therapy, and willing to participate in the study treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1. Participants with learning disabilities (e.g., intellectual disability, developmental delays, or speech delays). 2. Failure to meet the inclusion criteria specified by the clinical research protocol. 3. Presence of severe organic diseases affecting the cardiovascular, hepatic, renal, hematopoietic, or nervous systems, such as chronic nephritis, hepatitis, congenital heart disease, chorea, subacute encephalitis, etc. 4. Comorbidity with conduct disorder, pervasive developmental disorder, intellectual disability, mood disorders, or schizophrenia, among other mental health issues. 5. Inability to complete the full course of treatment, resulting in an inability to assess treatment efficacy or having incomplete data that affects the evaluation of efficacy or safety.

Design outcomes

Primary

MeasureTime frame
YGTSS (Yale Global Tic Severity Scale);PUTS (Premonitory Urge for Tics Scale);

Secondary

MeasureTime frame
MEI related metrics;

Countries

China

Contacts

Public ContactZang Yufeng

Hangzhou Normal University Affiliated Hospital

zangyf@hznu.edu.cn+86 186 0651 7380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026